Koite-Dwi

Coate-DVI: hemostatic agent based on blood coagulation factor VIII

Coate-DVI is a hemostatic agent that is used to treat bleeding in patients with hemophilia A (coagulation factor VIII deficiency). It is produced in the form of a lyophilisate for the preparation of a solution for injection or intravenous administration.

Coate-DVI is manufactured in the United States by two companies - Bayer AG and Talecris Biotherapeutics Inc. The drug belongs to the group of hemostatic drugs that are used to accelerate blood clotting and stop bleeding.

The main active ingredient in Coate-DVI is blood clotting factor VIII, which plays an important role in the blood clotting process. Under normal conditions, this factor is produced in the body independently, but in patients with hemophilia A its level is insufficient, which leads to impaired blood clotting and an increased risk of bleeding.

Coate-DVI is presented on the market with many synonyms, such as Actif VIII-Antihemophilic factor, Hemoctin SDT, Hemophil M, Immunat, Cohenate FS, Coate-NR, Cryobulin TIM 3 (Human Factor VIII concentrated), Cryoprecipitate, Cryoprecipitate dry, Cryostat SD- 2, Monoclat-P, Octavi, Octanate, Recombinant, Uman Kra.

Dosage forms of Coate-DVI vary depending on the dosage and route of administration. Lyophilisate for the preparation of solution for injection is available in dosages of 200-300IU, 400-600IU and 800-1300IU. There is also a lyophilisate for preparing a solution for intravenous administration in a dosage of 200.

Coate-DVI has become one of the most effective and safe means for the treatment of bleeding in patients with hemophilia A. However, before starting to use this drug, you must consult with your doctor and strictly follow the recommendations for dosage and method of administration.